

February 26, 2019



# Ceapro Inc. Announces Three Abstracts Selected for Oral Presentation at the 17th European Meeting on Supercritical Fluids (EMSF 2019)

**- Important research findings from collaboration with University of Alberta demonstrating potential of Ceapro's unique enabling PGX technology to produce innovative delivery systems -**

EDMONTON, Alberta, Feb. 26, 2019 (GLOBE NEWSWIRE) -- [Ceapro Inc. \(TSX-V: CZO\)](#) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that its collaborators from University of Alberta will present at the [17<sup>th</sup> European Meeting on Supercritical Fluids](#) (EMSF 2019) being held April 8-11, 2019 in Ciudad Real, Spain.

Summarized below are the abstracts that have been selected for oral presentation at EMSF 2019.

## Tuesday, April 9, 2019

**Time:** 3:15 PM CEST  
**Presenter:** Dr. Ricardo Couto  
**Abstract #33537:** *Drying biopolymers with Pressurized Gas eXpanded (PGX) liquids: polysaccharides vs proteins*

## Wednesday, April 10, 2019

**Time:** 10:45 AM CEST  
**Presenter:** Yonas Gebrehiwot  
**Abstract #33540:** *Pressurized Gas eXpanded (PGX) liquid drying of soy protein isolate*

**Time:** 12:45 PM CEST  
**Presenter:** Zixiang Liu  
**Abstract #33540:** *Drying of sodium alginate using Pressurized Gas eXpanded (PGX-SA) liquid technology*

Ceapro has conducted research on a number of various biopolymer samples from different sources. These studies conducted in collaboration with Dr. Feral Temelli's team at University of Alberta further demonstrate the versatility of PGX Technology. Results of these studies illustrate the potential to dry, purify, micronize and functionalize proteins, peptides, and polysaccharides that can lead to the development of highly potent bioactive delivery systems with desirable characteristics. Additionally, the studies demonstrate the potential to generate new material (PGX SA) that exhibits a unique fibrous structure, which can be very desirable for wound healing applications or bioactive delivery systems.

### **About EMSF 2019**

EMSF 2019 is organized by The International Society for Advancement of Supercritical Fluids (ISASF) and the Organizing Committee of the 17<sup>th</sup> European Meeting on Supercritical Fluids (EMSF). This is the 17<sup>th</sup> of a fruitful series of meetings, where Scientists, Students and Industry Partners discuss current developments and innovations based on the extraordinary properties of supercritical fluids. The meeting will be held in Ciudad Real (Spain), between 8-11th of April 2019. As in previous years, the conference will include sessions, plenary lectures, oral communications and poster sessions. For more information, please visit the conference website, [here](#).

### **About Ceapro Inc.**

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at [www.ceapro.com](http://www.ceapro.com).

### **For more information contact:**

Jenene Thomas  
Jenene Thomas Communications, LLC  
Investor Relations and Corporate Communications Advisor  
T (US): +1 (833) 475-8247  
E: [czo@jtcir.com](mailto:czo@jtcir.com)

Issuer:

Gilles R. Gagnon, M.Sc., MBA  
President & CEO  
T: 780-421-4555

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the*

*adequacy or accuracy of this release*



Source: Ceapro Inc.